Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session
Myriad Genetics, Inc. MYGN was a big mover last session, as the company saw its shares rise around 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 35.7% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate, however, moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this biomedical stock going forward to see if this recent move higher can last.
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
MYRIAD GENETICS Price
MYRIAD GENETICS Price | MYRIAD GENETICS Quote
A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. ANIP, sporting a Zacks Rank #1 (Strong Buy).
Is MYGN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
